Chugai Pharmaceutical Co., Ltd. is one of Japan’s leading research-based pharmaceutical companies, renowned for its strengths in biotechnology and antibody engineering. As a core member of the Roche Group, Chugai is dedicated to developing innovative drugs and services to address unmet medical needs globally, with a primary focus on oncology, bone and joint diseases, and renal diseases. Their mission is to add exceptional value by creating and delivering innovative medical products and services for the benefit of the medical community and human health around the world. Chugai strives for 'Innovation beyond imagination' to transform healthcare.
The headquarters in Tokyo serves as the central hub for Chugai's global operations, overseeing strategic planning, corporate management, research and development direction, and administrative functions.
Located in the modern Nihonbashi Muromachi Mitsui Tower, the headquarters likely features state-of-the-art facilities, advanced sustainable building technologies, and collaborative workspaces designed to foster innovation.
Chugai's work culture emphasizes patient-centricity, innovation, and ethical practices. It fosters an environment of collaboration and continuous learning, encouraging employees to take on new challenges to realize 'Innovation beyond imagination'. Diversity and inclusion are also key aspects of their corporate culture.
The Tokyo headquarters is strategically important, anchoring Chugai's operations in its home market of Japan and serving as a critical link within the global Roche network. Its location in Nihonbashi, a prominent business district, underscores its status as a leading pharmaceutical company.
Chugai Pharmaceutical operates globally, with a strong presence in Japan and key international markets. Its functions supported globally include research and development (with research sites in Japan and Singapore), manufacturing (primarily in Japan), clinical development (conducted worldwide including North America and Europe), and sales and marketing activities, often in collaboration with Roche. Chugai aims to deliver its innovative medicines to patients around the world, leveraging its own capabilities and the Roche Group's extensive network.
Nihonbashi Muromachi Mitsui Tower, 1-5-10 Nihonbashi-muromachi
Chuo-ku
Tokyo
Japan
Address: One NewChange, London, EC4M 9AF, United Kingdom (Example for Chugai Pharma Europe Ltd. Actual US address for Chugai Pharma USA, Inc. is typically in Berkeley Heights, NJ or similar pharma hub)
To conduct clinical trials, engage with regulatory authorities like the FDA, and collaborate with medical experts and institutions in the United States, a key market for pharmaceutical innovation.
Address: 3 Biopolis Drive, #05-11/12 Synapse, Singapore 138623
To leverage Singapore's vibrant biomedical research ecosystem and talent pool for cutting-edge drug discovery, contributing novel therapeutic candidates to Chugai's global pipeline.
Address: Building 1, Chiswick Park, 566 Chiswick High Road, London W4 5YA, United Kingdom
To manage and execute clinical trials across European countries, secure regulatory approvals, and provide medical support for Chugai's therapies in the European market.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Chugai Pharma USA, Inc.' leadership includes:
Chugai Pharma USA, Inc. has been backed by several prominent investors over the years, including:
Chugai Pharmaceutical announced several key executive promotions and director changes effective early 2024, reflecting strategic leadership adjustments and board refreshment as part of its ongoing commitment to governance and growth.
Discover the tools Chugai Pharma USA, Inc. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Chugai Pharmaceutical Co., Ltd. primarily uses the email domain chugai-pharm.co.jp. While exact patterns can vary, a common format for corporate emails in Japan is [first].[last] or [first_initial][last].
[first].[last]@chugai-pharm.co.jp
Format
taro.yamada@chugai-pharm.co.jp
Example
75%
Success rate
Chugai Pharmaceutical Co., Ltd. Official Website • March 1, 2024
Chugai announced that the European Commission approved Enspryng (satralizumab) as the first and only treatment option for children aged six years and older with aquaporin-4 antibody (AQP4-IgG)-seropositive neuromyelitis optica spectrum disorder (NMOSD). This marks a significant advancement for pediatric patients with this rare autoimmune disease....more
Chugai Pharmaceutical Co., Ltd. Official Website • February 29, 2024
Chugai filed a new drug application with the Japanese Ministry of Health, Labour and Welfare for nemolizumab, an anti-interleukin-31 (IL-31) receptor A humanized monoclonal antibody, for the treatment of pruritus associated with atopic dermatitis in adult and adolescent patients. This follows positive results from Phase III clinical trials....more
Chugai Pharmaceutical Co., Ltd. Official Website • February 7, 2024
Chugai announced its consolidated financial results for the fiscal year ended December 31, 2023, reporting Core EPS of 219.0 yen. The company highlighted strong performance driven by its global products and outlined its financial forecasts and strategic priorities for 2024, emphasizing continued R&D investment and growth....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Chugai Pharma USA, Inc., are just a search away.